Quivive Pharma
Private Company
Funding information not available
Overview
Quivive Pharma is a private, preclinical-stage biotech addressing the opioid overdose epidemic through a novel drug delivery and safety platform. Its lead strategy involves repurposing Doxapram, an FDA-approved drug, as a functional antagonist to counteract opioid-induced respiratory depression—the primary cause of overdose deaths—while preserving analgesia. The company aims to develop abuse-deterrent opioid formulations that close a significant safety gap left by current products and address the major gateway to opioid addiction.
Technology Platform
Functional antagonism platform using Doxapram to counteract opioid-induced respiratory depression and other side effects without impacting analgesia, combined with a pharmacological abuse-deterrence technology.
Opportunities
Risk Factors
Competitive Landscape
Competes against developers of non-opioid analgesics, novel opioid agonists with improved safety profiles, and existing abuse-deterrent formulations (which Quivive argues are insufficient). Also faces competition from naloxone-based rescue therapies, which are reactive rather than preventive.